Grail CSO Vikram Ba­jaj jumps to VC firm Fore­site, takes lead on per­son­al­ized meds

Af­ter just one year on the job, Vikram Ba­jaj has left his post as chief sci­en­tif­ic of­fi­cer of can­cer biotech Grail and is join­ing in­vest­ment firm Fore­site Cap­i­tal as man­ag­ing di­rec­tor.

San Fran­cis­co-based Fore­site, a VC and pri­vate eq­ui­ty firm with $1.2 bil­lion in as­sets un­der man­age­ment, will lever­age Ba­jaj’s back­ground in ge­net­ics and da­ta sci­ence to find in­vest­ment op­por­tu­ni­ties in per­son­al­ized med­i­cine. Jim Tanan­baum, Fore­site’s CEO, told Ax­ios that hir­ing Ba­jaj is about ex­pand­ing the firm’s ar­eas of ex­per­tise. He thinks per­son­al­ized med­i­cine is a safe bet.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER